RxDoctor Payments Data

Duyen Magnuson

Nurse Practitioner · Garland, TXNPI 1558043570

Payments from drug & device makers

$767in general payments, 2019–2025

Across 38 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$167
  • AbbVie$129
  • Exact Sciences$90
  • Novo Nordisk$65
  • Amgen$50
  • Kowa Pharmaceuticals America, Inc.$43
  • plus $222 from 9 others

What the payments were for

  • Food & beverage$767100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$767 in reported general payments places this provider in the 70th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$13,971
Medicare patients
77
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$63,631
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$48,590
TrulicityDulaglutide14$20,109
JardianceEmpagliflozin14$19,960
MounjaroTirzepatide12$18,222
Tresiba Flextouch U-100Insulin Degludec11$7,162
Albuterol Sulfate HfaAlbuterol Sulfate144$4,381
Nano 2nd Gen Pen NeedlePen Needle, Diabetic18$2,443
Tizanidine Hcl50$1,697
Atorvastatin Calcium204$1,530
Gabapentin68$1,201
Losartan Potassium117$941
Ventolin HfaAlbuterol Sulfate12$768
Fluticasone Propionate36$604
Oxybutynin Chloride ErOxybutynin Chloride23$590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$65$63,63149 claims
GSKTrelegy Ellipta$167$48,59058 claims
Lilly USA, LLCTrulicity, Mounjaro$15$38,33126 claims
Boehringer IngelheimJardiance$28$19,96014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Garland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →